TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16820580
Drug: T3 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3 (0.8 microg.kg(‐1) followed by 0.113 microg.kg(‐1) h(‐1)) administered for a 6-hour period from removal of AXC
Study: 2442417
Drug: Sodium pentosanpolysulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium pentosanpolysulfate (Elmiron) 100 mg, 3 times daily for a minimum of 4 months
Study: 23129412
Drug: Idebenone (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (450 mg/d)
Study: 18817987
Drug: physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological solution
Study: 17058823
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection before CPB
Study: 17058823
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection after CPB
Study: 17058823
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Shenfu Injection)
Study: 12730149
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline for 20 minutes
Study: 12730149
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline
Study: 10391422
Drug: oral microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral microemulsion CsA 5 mg/kg
Study: 10391422
Drug: intravenous CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous CsA 1.5 mg/kg
Study: 1642943
Drug: Partial denitrogenation
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial denitrogenation by breathing oxygen from the start of injection of the induction agent
Study: 6377970
Drug: Kallikrein 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein 600 K.U. daily for 3 months
Study: 30917531
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 100,000 IU soft capsule (Group 1)
Study: 30917531
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 100,000 IU oral solution in ampoule (Group 2)
Study: 24806873
Drug: Stepwise Protocol
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise Protocol of Treating Pain (individual daily pain treatment with paracetamol, extended release morphine, buprenorphine transdermal patch or pregabaline for 8 weeks)
Study: 19050388
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation (episodic use of antiretroviral therapy guided by CD4 cell count)
Study: 19050388
Drug: Viral suppression
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral suppression (continuous antiretroviral therapy)
Study: 27432436
Drug: Inactivated FVRCP
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated FVRCP vaccine
Study: 27432436
Drug: Modified live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified live FVRCP vaccine
Study: 19548437
Drug: Combined hormonotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hormonotherapy with Chinese drugs for detoxifying
Study: 16426798
Drug: Haptotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haptotherapy treatment (5 sessions of 45 minutes each)
Study: 14707013
Drug: High exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exercise level (Hex; approximately 4 MJ/day) with high-fat diet (HF; 50% of energy, 700 kJ/100 g)
Study: 14707013
Drug: High exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exercise level (Hex; approximately 4 MJ/day) with low-fat diet (LF; 20% of energy, 300 kJ/100 g)
Study: 14707013
Drug: No exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercise (Nex; control) with high-fat diet (HF; 50% of energy, 700 kJ/100 g)
Study: 14707013
Drug: No exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercise (Nex; control) with low-fat diet (LF; 20% of energy, 300 kJ/100 g)
Study: 14707013
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet (HF; 50% of energy, 700 kJ/100 g)
Study: 14707013
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (LF; 20% of energy, 300 kJ/100 g)
Study: 6285406
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg CBD
Study: 28793785
Drug: Pictorial aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictorial aid intervention (photographic representation of medications, indications, and dosing schedule)
Study: 28793785
Drug: Standard clinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinic visit discharge medication list (control)
Study: 24194508
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg four times a day)
Study: 15929052
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1 x 10(8) autologous MSCs (n = 5)
Study: 10102961
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg, metronidazole 500 mg, and clarithromycin 500 mg, all twice daily for 1 week (RMC)
Study: 10102961
Drug: Amoxycillin 1000
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1000 mg substituted for clarithromycin (RMA)
Study: 7572746
Drug: Soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy formula with ascorbic acid at 625 mumol/L (110 mg/L)
Study: 7572746
Drug: Soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy formula with ascorbic acid at 1250 mumol/L (220 mg/L)
Study: 2405811
Drug: Isokinetic concentric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isokinetic concentric training on a Cybex II+ isokinetic dynamometer, three days weekly for six weeks, five sets of ten maximal effort knee extensions at 1.05 rad/s
Study: 7441660
Drug: naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (750 mg/d)
Study: 7441660
Drug: indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin (100 mg/d)
Study: 31773764
Drug: Oral antiglycemic
Normalized name: ANTILIPEMIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiglycemic medication and insulin
Study: 30907034
Drug: FMPBE (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMPBE (250 mg/day, n = 21)
Study: 30907034
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg starch/day, n = 19)
Study: 29084159
Drug: Association with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association with monthly living expenses
Study: 26030346
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate 80 mg/day
Study: 26030346
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate 160 mg/day
Study: 26030346
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate 240 mg/day
Study: 19836748
Drug: Flat patch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat patch mesh
Study: 19836748
Drug: Double-sided patch
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-sided patch
Study: 17691589
Drug: Fe-59 labeled
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer), 100 mg elemental iron
Study: 17691589
Drug: Fe-59 labeled
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer) combined with 600 mg aluminium hydroxide (10 ml)
Study: 15761783
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg bid)
Study: 15761783
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg bid)
Study: 15761783
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of N-acetylcysteine and Vitamin C (600 mg NAC and 500 mg Vitamin C bid)
Study: 15761783
Drug: N-acetylcysteine, Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine, Vitamin C, and NAC/Vitamin C combination
Study: 10421142
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of sulbactam plus ampicillin (group 1)
Study: 10421142
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefazolin (group 2)
Study: 8889287
Drug: Control (neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neuroleptic drugs)
Study: 26427987
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with combined application of MMC (0.4 mg/ml for 3 min) and bevacizumab (2.5 mg in 0.2 ml)
Study: 26427987
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with application of MMC (0.4 mg/ml for 3 min) only
Study: 22119634
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 15 mg (Group B)
Study: 22119634
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 12 mg with fentanyl 15 μg (Group BF)
Study: 19221727
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg three times daily for 14 days
Study: 18372698
Drug: Nutrition (Nut:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition (Nut: daily protein supplement)
Study: 9541719
Drug: Troglitazone (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200-600 mg once daily)
Study: 9541719
Drug: Troglitazone added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone added to sulfonylureas or insulin
Study: 2114133
Drug: General practitioners
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioners receiving extended waiting time information for hospital consultation and treatment in general surgery.
Study: 380952
Drug: 1% (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% (2.5 mg) reproterol aerosol
Study: 380952
Drug: 2% (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% (5 mg) reproterol aerosol
Study: 25835492
Drug: Vitamin D3,
Normalized name: Vitamin D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3, 30000 IU given orally once weekly for 8 weeks
Study: 19236467
Drug: Ginsenoside-Rd 10
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside-Rd 10 mg (group A)
Study: 19236467
Drug: Ginsenoside-Rd 20
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside-Rd 20 mg (group C)
Study: 19236467
Drug: Ginsenoside-Rd (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside-Rd (both doses)
Study: 17958849
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 15% Ointment
Study: 17958849
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 10% Cream
Study: 15493847
Drug: Domestic octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic octreotide injection (200 microg, intramuscular)
Study: 15493847
Drug: Imported octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported octreotide injection (200 microg, intramuscular)
Study: 15493847
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of domestic and imported octreotide injections
Study: 7944845
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in hospitals with coronary revascularization services
Study: 7944845
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in small hospitals with coronary revascularization facilities
Study: 7944845
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in hospitals without coronary revascularization services
Study: 7944845
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in smaller hospitals
Study: 3308186
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg daily
Study: 3308186
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg daily
Study: 3308186
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg daily
Study: 20852871
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg once daily for 6 weeks
Study: 19014770
Drug: Budesonide (inhaled),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (inhaled), administered twice daily
Study: 19014770
Drug: Bronchodilator (albuterol)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (albuterol)
Study: 19014770
Drug: Placebo (inhaled)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inhaled)
Study: 14567121
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol gel (1.5 mg/day) plus nomegestrol acetate (5 mg/day)
Study: 14567121
Drug: Oral equine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral equine sulfoconjugated estrogen (0.625 mg/day) plus nomegestrol acetate (5 mg/day)
Study: 2681331
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 3.2 mg per day
Study: 2681331
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) 40 mg per day
Study: 2681331
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 2.0 mg per day
Study: 2681331
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) ≥ 1.84 mg/day/70 kg
Study: 2681331
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) ≥ 15 mg per day
Study: 57959
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release decongestant combination
Study: 57959
Drug: Full triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full triple-drug capsule
Study: 28270380
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vital signs with a robust algorithm based on machine learning
Study: 26387946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of endocrine therapy with targeting JAG1-NOTCH4
Study: 23750462
Drug: CBASP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBASP plus antidepressant medication
Study: 21852067
Drug: Wavefront-optimized PRK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wavefront-optimized PRK (Allegretto Wave Eye‐Q software version 2.020 default treatment)
Study: 17920505
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of oral ibuprofen
Study: 17920505
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of oral paracetamol
Study: 11574180
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg 17beta‐estradiol/0.15 mg desogestrel (n=53)
Study: 11574180
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogens/0.15 mg norgestrel (n=36)
Study: 9623427
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 75 mg (group A; n = 15)
Study: 9623427
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 75 mg‐ketamine 0.3 mg kg‐1 (group B; n = 14)
Study: 9623427
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 75 mg‐ketamine 0.5 mg kg‐1 (group C; n = 5)
Study: 9623427
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 75 mg‐ketamine 0.67 mg kg‐1 (group D; n = 15)
Study: 7836627
Drug: 142 mg
Normalized name: phentermine 142 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 142 mg Zn as Zn sulfate (ZnSO4) during Ca intakes of 230, 500 and 800 mg/day
Study: 7836627
Drug: 142 mg
Normalized name: phentermine 142 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 142 mg Zn as Zn sulfate (ZnSO4)
Study: 31795895
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in MR CLEAN trial
Study: 31795895
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in IMS III trial
Study: 29209514
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (6 capsules of 1g daily, totaling 3.6g LCn-3PUFA)
Study: 16884779
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 0.05% 4 times a day
Study: 16884779
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 0.05% with pulsed prednisolone acetate 1% dosing
Study: 16884779
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control subjects using topical steroids
Study: 10322817
Drug: Huoxue Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxue Tablet
Study: 12585189
Drug: Composite Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Danshen tablet
Study: 8110625
Drug: Defibrotide (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (group D): day 0, 3.6 g by intravenous infusion in 12 hours; days +1 to +6, 800 mg tid intravenously; days +7 to +10/+12, 400 mg tid intramuscularly
Study: 8110625
Drug: Heparin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (group H): day 0, 1000 IU/hour infused over 12 hours; days +1 to +10/+12, 5000 IU tid subcutaneously
Study: 8110625
Drug: Heparin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (group H)
Study: 3314717
Drug: 2% to
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% to 3% topical minoxidil solution
Study: 3314717
Drug: 3% topical
Normalized name: Triaz 3% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% topical minoxidil solution
Study: 27974311
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical nutrition therapy with energy intakes at nationally recommended amounts
Study: 21072684
Drug: IMSI (Intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMSI (Intracytoplasmic Morphologically Selected Sperm Injection)
Study: 15136972
Drug: L-arginine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (200 mg/kg) after treatment with ramipril (5 mg/day)
Study: 15136972
Drug: L-arginine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (200 mg/kg) after treatment with losartan (50 mg/day)
Study: 15136972
Drug: L-arginine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine alone
Study: 15136972
Drug: L-arginine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine after treatment with ramipril or losartan
Study: 11591569
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide inhalation aerosol, 42 microg
Study: 31247132
Drug: CBD capsules
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD capsules administered with food (high fat 840‐860 calorie)
Study: 31247132
Drug: CBD capsules
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD capsules administered without food (fasting)
Study: 29254862
Drug: Ceftazidime-avibactam (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime-avibactam (2000 mg ceftazidime and 500 mg avibactam by 2 h intravenous infusion every 8 h for 7-14 days)
Study: 29254862
Drug: Meropenem (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1000 mg by 30-min intravenous infusion every 8 h for 7-14 days)
Study: 22648717
Drug: Magnesium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (300 mg/d)
Study: 16523808
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose escalation
Study: 22770932
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (2 * 15 g, twice daily)
Study: 19509020
Drug: Low-dose cortisol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cortisol infusion (physiologic levels during hypoglycemia)